Objective To study the effect of mosapride citrate in the treatment of gastroesophageal reflux disease and its effect on gastrin .Methods 86 patients with gastroesophageal reflux disease admitted in our hospital from August 2013 to August 2016, those patients were divided into observation group and control group according to the order of admission,43 cases in each group.The control group was treated with esomeprazole on the basis of basal therapy, and the observation group was treated with mosapride citrate on the basis of control group.The clinical curative effect and adverse reaction were analyzed,visual analogue scale(VAS), gastrin and motilin were compared before and after treatment between the two groups.Results After treatment, the total effective rate in the observation group was significantly higher than the control group [90.70% (39/43) vs.65.12% (28/43)](P<0.05). The VAS score in the observation group was significantly lower than the control group [(2.43 ±0.25) vs.(4.02 ±0.41)](P<0.05).The levels of gastrin and motilin in the observation group were significantly higher than the control group[ (55.87 ±4.82) pg/mL, (308.43 ±19.31) pg/mL vs. (44.12 ±3.86) pg/mL,(243.12 ±15.76) pg/mL](P<0.05).There was no significant difference in adverse reaction rate between two groups. Conclusion Mosapride citrate tablets can be used in gastroesophageal reflux disease , can effectively improve the patient's gastrin levels and clinical symptoms, clinical efficacy is good, and with low rate of adverse reactions.

AIM:To explore the effect of neuropeptide Y on expression of apoptosis associated genes and proliferation in vascular smooth muscle cells(VSMC). METHODS: The proliferation activity of VSMC was dterminded by MTT colorimetry. The average fluorescence intensity that represented VSMC nuclear antigen (PCNA) and bcl-2, bax, fas expressions was quantitatively measured by fluorescence immunohistochemistry. RESULTS: Compared with control, the expressions of bcl-2, bax, fas, PCNA and the VSMC proliferation activity in VSMC treated with NPY were significantly increased. CONCLUSION:NPY may increase the expression of apoptosis associated genes in VMSC and promote its proliferation.

【Objective】 To explore the mechanism of action of Losa rtan on vascular remodelling in hypertension and its relationship with neuroendo crine factor and renin-angiotensin system.【Methods】 The study consisted of co ntrol group and other three treatment groups: Losartan group、NPY group、and Los artan+NPY group. More than 200 cells were scanned in each group. The methods of c ellular culture, biochemistry and quantitative immunocytochemistry through ACAS5 70 were applied to investigate the proliferation of vascular smooth muscle cell (VSMC) and the expression of proliferating cell nuclear antigen (PCNA) in cultur ed rat VSMC treated with Losartan and Neuropeptide Y (NPY) stimulation. 【Result s】 VSMC proliferation (by absorbauce) in the control group and other three exam ed groups: Losartan group、NPY group and Losartan+NPY group were 0.223 9±0.00 1 0、0.204 5±0.001 3、0.262 6±0.002 5、0.244 0±0.001 3, and PCNA (by fl uorescence intensity) were 1 543±200、1 339±233、1 649±233、1 545±256. It wa s observed that losartan could inhibit the VSMC proliferation in vitro cultu re with and without NPY simulation. Compared with the control groups, the VSMC p roliferation activity and expression of PCNA were obviously descreased in the lo sartan treated gro ups. 【Conclusion】 The results demonstrate that losartan has the inhibitive eff ects on VSMC profiferation and PCNA expression. The results also suggest that lo sartan has anti-NPY effect on VSMC in vascular remodelling of hypertensive vess els.

AIM: To explore the effect of neuropeptide Y on expression of apoptosis associated genes and proliferation in vascular smooth muscle cells(VSMC). METHODS: The proliferation activity of VSMC was dterminded by MTr colorimetry. The average fluorescence intensity that represented VSMC nuclear antigen (PCNA) and bcl -2, bax, fas expressions was quantitatively measured by fluorescence immunohistoehemistry. RESULTS: Compared with control, the expressions of bcl - 2, bax, fas, PCNA and the VSMC proliferation activity in VSMC treated with NPY were significantly increased. CONCLUSION: NPY may increase the expression of apoptosis associated genes in VMSC and promote its proliferation.

OBJECTIVE:To bring the computer network into full play in effectively monitoring therapeutic recipe for patients to realize individualized administration of drugs.METHODS:According to the phasic characteristics of forming recipe, a local network model for monitoring therapeutic recipe has been set up.RESULTS & CONCLUSION:By computer and local network monitoring, the quality of prescription can be improved and individualized administration of drugs will further be achieved.

Objective:To evaluate the efficacy and safety of lenvatinib combined with camrelizumab as the second-line treatment for advanced intrahepatic cholangiocarcinoma (ICC).Methods:The clinical data of patients with advanced ICC undergoing the second-line treatment of lenvatinib combined with camrelizumab in the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University from June 2021 to June 2022 were screened and analyzed. A total of 12 patients were enrolled, including seven males and five females, aged (67.5±8.6) years. Response evaluation criteria in solid tumor 1.1 was used to evaluate the efficacy of treatment. The safety assessment adopts the Adverse Event Evaluation Standard 5.0. Kaplan-Meier method was conducted to plot survival curves.Results:Among the 12 patients (after 1-7 cycles of immune and targeted therapy), three achieved partial response, four achieved stable disease, and five were defined as progression disease. Adverse events of different degrees occurred in seven cases, among which three patients had adverse events of grade ≥ 3: one with hypertension, which was managed after antihypertensive and symptomatic treatment; one with elevated serum total bilirubin, which was improved after reducing the dose of lenvatinib; one with liver dysfunction, which was considered as immune-related liver toxicity and alleviated after discontinuing camrelizumab. The 1-month, 3-month, and 6-month survival rates and progression-free survival rates of the patients were 100.0%, 91.7%, 66.7%, and 83.3%, 41.7%, and 25.0%, respectively. The median overall survival of patients was 14.7 months (95% CI: 9.2-21.2) and the median time to progression was 8.0 months (95% CI: 4.1-11.9). Conclusion:Combination of lenvatinib and camrelizumab could bring survival benefits with controllable adverse events as the second-line treatment of patients with advanced ICC.

Additive manufacturing(3D printing)technology aligns with the direction of precision and customization in future medicine,presenting a significant opportunity for innovative development in high-end medical devices.Currently,research and industrialization of 3D printed medical devices mainly focus on nondegradable implants and degradable implants.Primary areas including metallic orthopaedic implants,polyether-ether-ketone(PEEK)bone implants,and biodegradable implants have been developed for clinical and industrial application.Recent research achievements in these areas are reviewed,with a discussion on the additive manufacturing technologies and applications for customized implants.Challenges faced by different types of implants are analyzed from technological,application,and regulatory perspectives.Furthermore,prospects and suggestions for future development are outlined.